Social distancing may be necessary for two years or more. Here's where remote care comes into play.

Partner and CMO, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Specialty drugs represent an opportunity to better serve patients, but also pose risks.

Partner, Health and Life Sciences, Oliver Wyman
Principal, Actuarial, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman
Director, Marsh & McLennan Advantage, Healthcare

The recent rise of custom-made drugs is already redefining the state of regulation, society, and the economy.

Researcher, PreScouter

In our rearview mirror is a ten-year stretch of experimentation. What looms ahead is the rewriting of healthcare's rules.

Partner, Health and Life Sciences, Oliver Wyman
Former Partner, Health & Life Sciences, Oliver Wyman
Principal, Health & Life Sciences, Oliver Wyman

Whoever's closest to the consumer will be the gatekeeper of the industry.

Partner, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman

Insights in your inbox

Subscribe

Three percent of consumers drive 70 percent of pharmacy spend. Pharmacy is ripe for change.

Former Partner, Health & Life Sciences, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Senior Advisor, Oliver Wyman

It's time to get comfortable with being uncomfortable.

Partner, Health and Life Sciences, Oliver Wyman

How measurement and monitoring will wake physicians up to their dangerous, unnecessary, (and unintentional) prescribing habits.

Global Head, Health Services, Oliver Wyman

How to ensure medications work as intended for different patient populations.

Chief Executive Officer, Aetion
Partner, Health and Life Sciences, Oliver Wyman

There's big buzz around consumer behavior driving outcomes. But clinical data doesn't yet align with behavioral data.

Partner, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe
Load More